Smith & Nephew plc (ADR) (NYSE:SNN)

CAPS Rating: 4 out of 5

The Company is a global business engaged in the development, manufacture and marketing of medical devices in the sectors of orthopaedic reconstruction, orthopaedic trauma and clinical therapies, endoscopy and advanced wound management.

Recs

0
Player Avatar sk8jeff1 (67.89) Submitted: 5/23/2009 9:53:06 AM : Outperform Start Price: $34.18 SNN Score: -12.79

Smith and Nephew is a large and safe company. SNN is near a 52 week low. Nothing about SNN itself has caused this drop in stock price. The costs of lending, oil prices and the generally poor economy have caused this stock to drop. SNN has a couple of new products in the final stages of development that will be used by orthopedic surgeons within the next year.SNN is widely regarded in the medical community for making safe, reliable and innovative products. They consult with and are counseled by physicians in Boston when making these products. There is no reason to believe their new products will not be just as successful as their past products. Get this stock near its 52 week low. It will pay you dividends and the price will grow.

Featured Broker Partners


Advertisement